The need for disruptive innovation in pharma has reached a precipice. In order to compete in the era of stratified medicine, cost-effectiveness considerations, and overall patient empowerment, the industry must rethink every aspect of the drug development continuum.
"And that is quite likely the biggest barrier to advocates of patient centered clinical trials today: not that they will be resisted, but that their message will be co-opted and their efforts shunted into high-visibility but low-impact initiatives".
Paul Ivsin explains how our attempts to make clinical trials more patient-friendly have, for the most part, been subverted by the need to collect more comprehensive and more patient-relevant data, which can prove burdensome to the patient.
Clinical trials represent one important area where digitization is set to transform the pharma landscape, as social networks bring faster and more targeted recruitment of participants, writes Nick de Cent.
Jack Whelan, ePatient and clinical trial proponent on how pharma needs to push the regulatory boundaries to fully engage with the patient and how a strict regulatory environment is hampering meaningful dialogue between pharma and the patient
It is a truth universally acknowledged that in this tough payer climate, pharma must slash costs. Software companies offer opportunities to streamline the clinical trial process from design to analysis, promising to save the industry at least US$3.7billion across phase II and phase III trials.
Clinical trials as we know it are over. Their annual cost is unsustainable and solutions that curtail these expenses must be put in place. Luckily, big data offers unprecedented opportunities that will revolutionize research.